Literature DB >> 23076400

Dysregulation of signaling pathways and putative biomarkers in liver cancer stem cells (Review).

Kai Song1, Junhua Wu, Chunping Jiang.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common tumors in the world. At present, the details of the mechanism responsible for HCC formation and maintenance remain unclear. However, the cancer stem cell (CSC) theory suggests that liver cancer stem cells (LCSCs) may be responsible for the biological characteristics of HCC. Dysregulation of signaling pathways, including transforming growth factor β (TGF-β), Wnt, Notch and Hedgehog pathways, has been found to be involved in the process of hepatocarcinogenesis and is considered the key determinant of LCSC function. Numerous LCSC biomarkers have been identified including CD133, epithelial cell adhesion molecule (EpCAM), ABCG2 and CD90, which would contribute to the isolation of LCSCs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23076400     DOI: 10.3892/or.2012.2082

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  14 in total

1.  Role for putative hepatocellular carcinoma stem cell subpopulations in biological response to incomplete thermal ablation: in vitro and in vivo pilot study.

Authors:  Scott M Thompson; Matthew R Callstrom; Kim A Butters; Shari L Sutor; Bruce Knudsen; Joseph P Grande; Lewis R Roberts; David A Woodrum
Journal:  Cardiovasc Intervent Radiol       Date:  2014-01-23       Impact factor: 2.740

Review 2.  Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care?

Authors:  Richard L Hesketh; Andrew X Zhu; Rahmi Oklu
Journal:  Am J Clin Oncol       Date:  2015-08       Impact factor: 2.339

3.  Genetic lineage tracing analysis of the cell of origin of hepatotoxin-induced liver tumors in mice.

Authors:  Soona Shin; Kirk J Wangensteen; Monica Teta-Bissett; Yue J Wang; Elham Mosleh-Shirazi; Elizabeth L Buza; Linda E Greenbaum; Klaus H Kaestner
Journal:  Hepatology       Date:  2016-05-28       Impact factor: 17.425

Review 4.  Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy.

Authors:  Chuan Chen; Ge Wang
Journal:  World J Hepatol       Date:  2015-07-28

5.  Oncogenic Wnt3a expression as an estimable prognostic marker for hepatocellular carcinoma.

Authors:  Liu-Hong Pan; Min Yao; Yin Cai; Juan-Juan Gu; Xu-Li Yang; Li Wang; Deng-Fu Yao
Journal:  World J Gastroenterol       Date:  2016-04-14       Impact factor: 5.742

Review 6.  Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells.

Authors:  Xiaoqi Huo; Shuanglin Han; Guang Wu; Olivier Latchoumanin; Gang Zhou; Lionel Hebbard; Jacob George; Liang Qiao
Journal:  Mol Cancer       Date:  2017-10-23       Impact factor: 27.401

7.  Autocrine Human Growth Hormone Promotes Invasive and Cancer Stem Cell-Like Behavior of Hepatocellular Carcinoma Cells by STAT3 Dependent Inhibition of CLAUDIN-1 Expression.

Authors:  Yi-Jun Chen; Ming-Liang You; Qing-Yun Chong; Vijay Pandey; Qiu-Shi Zhuang; Dong-Xu Liu; Lan Ma; Tao Zhu; Peter E Lobie
Journal:  Int J Mol Sci       Date:  2017-06-15       Impact factor: 5.923

Review 8.  Epigenetic Regulation of Hepatocellular Carcinoma Progression through the mTOR Signaling Pathway.

Authors:  Mengnan Guo; Ning Li; Jianxia Zheng; Wei Wang; Yan Wu; Xu Han; Jiapei Guo; Weixi Chen; Zekun Bai; Wen Bai; Jinghua Wu
Journal:  Can J Gastroenterol Hepatol       Date:  2021-05-25

9.  RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.

Authors:  Fei Wang; Ying Feng; Peng Li; Kun Wang; Liang Feng; Yi-Fei Liu; Hua Huang; Yi-Bing Guo; Qin-Sheng Mao; Wan-Jiang Xue
Journal:  Oncotarget       Date:  2016-01-26

Review 10.  Oncogenic Signaling Induced by HCV Infection.

Authors:  Alessia Virzì; Armando Andres Roca Suarez; Thomas F Baumert; Joachim Lupberger
Journal:  Viruses       Date:  2018-10-02       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.